Clinical Trials Companies in Europe

Boneprox provides services and products based on AI, machine learning and secure and efficient communication to the dental and health sector. Enabling clinics, dentists and doctors to become more efficient in sending, receiving, analyzing and diagnosing images and patients. In addition to this, Boneprox invests heavily in R&D and A.I to improve and streamline daily diagnostics as well as connect dental care and healthcare by finding patients at risk for systemic diseases based on dental X-ray images. Today, we have become the leader in digitalization within the industry. Boneprox has also developed Konekta, a digital specialist clinic that increases the availability of specialist competence and secures communication between specialists, clinics, dentists, and colleagues. The platform makes it possible to send digital referrals and questions to our connected specialists. With Konekta, our specialists are available as an extra resource and complement for the therapist when you need guidance from the right expertise. Today, it can take up to 15 months to get help from a specialist – Konekta gives an answer the same day. From innovation to reality!

Our mission is to create a comprehensive, patient-centric ecosystem that empowers individuals and healthcare professionals alike through a unique digital health platform to bring more quality of life for everyone.

Datacapt provides a global, easy-to-use, flexible, and powerful electronic data capture platform (EDC) for on-site, hybrid, or decentralized Clinical Trials. We allow Sponsors, CROs, and Subjects to work together in a simple way with a huge engagement. Our Platform brings simplicity, efficiency, and quality to the collection of clinical data. Datacapt is making the promise to simplify and accelerate clinical tests with innovative solutions. Simplify the management of your trial with the Datacapt platform. Developed with specialists and experts, our platform is flexible and adapted to your studies. We offer a modular platform with everything in one place to design and manage all your trials (EDC, eCRF, ePRO/eCOA/eDiary, eConsent, eConsult, and Data Analysis…). - Significantly reduced time spent on study setup and management (Simple and flexible eCRF, ePRO, eConsent creation) - Real-time monitoring - Allows reducing manual tasks, data retranscription, and zero time spent on data export - Fast and easy implementation - Secure and 100% Compliant

We want to provide people living with diabetes with an intelligent therapeutic system to regulate blood glucose. This project was initiated in 2011 by the CERITD (Centre d’Études et de Recherches pour l’Intensification du Traitement du Diabète) in collaboration with the CEA LETI. After the success of the clinical trials in 2014, we created Diabeloop to bring the project to market and make it available to the largest number of people. Since spring 2021, DBLG1 System, the first automated insulin delivery device, is being marketed in several European countries: Germany, Italy, Spain, Switzerland, the Netherlands and France.

Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses. Leveraging its unique oligoDOM® technology platform, OSIVAX is developing a universal vaccine for both current and future influenza infections. The Company’s universal flu vaccine candidate, OVX836 is in Phase 2a clinical development. OSIVAX is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. OSIVAX is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx’s first experimental medicine, efgartigimod, is being evaluated in multiple autoimmune diseases, including myasthenia gravis (MG), pemphigus vulgaris (PV), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). argenx is located in Ghent, Belgium, Boston, Massachusetts and Tokyo, Japan.

Centre de médecine esthétique à Labège (Toulouse). Eden Clinic est un lieu exclusivement consacré à la médecine esthétique, où chaque patient bénéficie d'une prise en charge médicale personnalisée. Les soins sont assurés par une équipe médicale composée de médecins et d'assistantes médicales qualifiées.

EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

AFYX Therapeutics is a private biopharmaceutical company focused on innovative approaches to treat mucosal diseases. The Company has developed the Rivelin patch, a breakthrough therapy for the treatment of mucosal diseases. Rivelin is designed to deliver a pharmaceutical drug uni-directionally to a mucosal surface using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface. AFYX's lead Rivelin patch product candidate seeks to treat the auto-immune, inflammatory disease oral lichen planus (OLP) through direct delivery of the drug clobetasol propionate. OLP may appear as lesions in the mouth that may cause burning, pain and other discomfort. OLP is considered an autoimmune disorder and requires regular monitoring given patients have increased risk of developing mouth cancer in the affected areas. No U.S. Food and Drug Administration (FDA) approved treatment exists, with today’s off-label treatment ranging from topical corticosteroids to laser ablation. It is estimated that OLP affects 1% to 2% of the population. Following successful results from a Phase 1b clinical study of the non-drug-loaded Rivelin patch in patients with OLP, AFYX has begun a Phase 2b clinical study of the clobetasol-loaded Rivelin patch in the United States and various countries in Europe. Shareholders include Sofinnova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.

Artificial Intelligence Enabled Medical Analytics and Diagnostics